{
    "hands_on_practices": [
        {
            "introduction": "This exercise provides a practical foundation for grading neuroendocrine tumors (NETs). The Ki-67 labeling index is a crucial biomarker that quantifies tumor proliferation, and its accurate determination is the first step in classifying a tumor's aggressiveness according to the World Health Organization (WHO) system. Mastering this calculation from raw pathological data is an essential skill for translating microscopic findings into a clinically actionable grade .",
            "id": "4836249",
            "problem": "A biopsy of a well-differentiated pancreatic neuroendocrine tumor (NET) is evaluated by immunohistochemistry (IHC) for proliferation using Ki-67 nuclear labeling. In three high-power hotspot fields, an experienced pathologist manually counted tumor nuclei, excluding endothelial cells, stromal cells, and lymphocytes. The aggregated count across these fields includes $500$ tumor nuclei, of which $35$ show unequivocal Ki-67 nuclear positivity. Using the recognized definition that the Ki-67 labeling index is the proportion of tumor nuclei with positive Ki-67 staining, compute the Ki-67 index as a decimal fraction. Then, using commonly applied World Health Organization (WHO) grading thresholds for gastrointestinal and pancreatic NETs based on Ki-67 index alone (well-differentiated NET Grade 1: $Ki-67  3\\%$, Grade 2: $3\\% \\le Ki-67 \\le 20\\%$, Grade 3: $Ki-67 > 20\\%$), determine the grade interval into which the calculated index falls. Express the final Ki-67 index as a dimensionless decimal fraction, rounded to three significant figures. Do not use a percentage sign in your final numerical answer. Your written assessment of grading implications should appear in your solution reasoning; the final boxed answer must be the Ki-67 index only.",
            "solution": "The problem statement is subjected to validation prior to any attempt at a solution.\n\n**Step 1: Extract Givens**\n- Total tumor nuclei counted: $500$\n- Number of Ki-67 positive tumor nuclei: $35$\n- Definition of Ki-67 labeling index: \"the proportion of tumor nuclei with positive Ki-67 staining\"\n- World Health Organization (WHO) grading thresholds for well-differentiated neuroendocrine tumors (NETs):\n  - Grade 1: $Ki-67  3\\%$\n  - Grade 2: $3\\% \\le Ki-67 \\le 20\\%$\n  - Grade 3: $Ki-67 > 20\\%$\n- Required output format: The Ki-67 index as a dimensionless decimal fraction, rounded to three significant figures.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is evaluated against the established criteria.\n- **Scientifically Grounded:** The problem uses standard, accepted terminology and methodology from the field of surgical pathology and oncology. The Ki-67 labeling index is a cornerstone for the grading of neuroendocrine tumors, and the provided WHO grading thresholds are current and accurate for gastrointestinal and pancreatic NETs. The data provided are realistic for a biopsy specimen.\n- **Well-Posed:** All necessary information for the calculation and subsequent classification is provided. The definition of the Ki-67 index is explicit, the counts are given, and the grading criteria are clearly defined. The instruction for rounding the final answer is unambiguous.\n- **Objective:** The problem is stated in precise, clinical language, free of subjective or ambiguous terms. It requests a quantitative calculation and a classification based on a formal system.\n\n**Step 3: Verdict and Action**\nThe problem is scientifically grounded, well-posed, objective, and internally consistent. It is therefore deemed **valid**. A solution will be derived.\n\nThe Ki-67 labeling index, denoted as $I_{\\text{Ki-67}}$, is defined as the proportion of tumor nuclei with positive Ki-67 staining. Let $N_{\\text{positive}}$ be the number of Ki-67 positive nuclei and $N_{\\text{total}}$ be the total number of tumor nuclei counted.\n\nThe given values are:\n- $N_{\\text{positive}} = 35$\n- $N_{\\text{total}} = 500$\n\nThe formula for the index is:\n$$I_{\\text{Ki-67}} = \\frac{N_{\\text{positive}}}{N_{\\text{total}}}$$\n\nSubstituting the given values into the formula:\n$$I_{\\text{Ki-67}} = \\frac{35}{500}$$\nThis fraction simplifies to:\n$$I_{\\text{Ki-67}} = \\frac{7}{100} = 0.07$$\n\nTo determine the grade, this decimal fraction must be expressed as a percentage by multiplying by $100\\%$:\n$$I_{\\text{Ki-67}} (\\text{in } \\%) = 0.07 \\times 100\\% = 7\\%$$\n\nNow, we apply the WHO grading thresholds:\n- Grade 1: $I_{\\text{Ki-67}}  3\\%$\n- Grade 2: $3\\% \\le I_{\\text{Ki-67}} \\le 20\\%$\n- Grade 3: $I_{\\text{Ki-67}} > 20\\%$\n\nSince our calculated index is $7\\%$, it satisfies the condition for Grade $2$, as $3\\% \\le 7\\% \\le 20\\%$. Therefore, the tumor is a well-differentiated neuroendocrine tumor, Grade $2$.\n\nThe problem requires the final answer to be the Ki-67 index as a dimensionless decimal fraction, rounded to three significant figures. The exact decimal value is $0.07$. To express this with three significant figures, we must represent it as $0.0700$. In this representation, the leading zeros are not significant, while the digit $7$ and the two trailing zeros are significant.",
            "answer": "$$\\boxed{0.0700}$$"
        },
        {
            "introduction": "Building upon the single-marker assessment, this problem addresses the integrated approach to grading required in practice. The WHO classification for NETs utilizes both the Ki-67 index and the mitotic count, and it is not uncommon for these two proliferative measures to suggest different grade categories. This exercise tests your ability to apply both criteria and, crucially, to understand the standard-of-care principle for resolving such discordance to ensure the most accurate prognostic classification .",
            "id": "4836148",
            "problem": "A $55$-year-old patient undergoes resection of a pancreatic mass. Histopathology shows a well-differentiated neuroendocrine neoplasm with organoid architecture and absence of small-cell or large-cell carcinoma morphology. Proliferation assessment reveals $14$ mitoses per $10$ high-power fields (HPF) and a Ki-67 labeling index of $18\\%$, determined by counting approximately $1000$ tumor nuclei within the highest-proliferation (“hot spot”) area. Based on established grading criteria for gastrointestinal and pancreatic neuroendocrine tumors, and the principle that tumor grade reflects proliferative aggressiveness, select the statement that most accurately identifies the World Health Organization (WHO) grade for this case and describes best-practice resolution when the mitotic rate and Ki-67 index are discordant.\n\nChoices:\n\nA. WHO Grade $2$ (intermediate), and when mitotic count and Ki-67 index are discordant, assign grade according to the higher category after verifying standardized hot spot counting, adequate sampling, and exclusion of non-tumor nuclei from Ki-67 counts.\n\nB. WHO Grade $3$ (high), because a mitotic count exceeding $10$ per $10$ HPF defines Grade $3$; and discordance should be resolved by averaging the Ki-67 percentage and mitotic count.\n\nC. WHO Grade $1$ (low), because Ki-67 less than $20\\%$ defines Grade $1$; and in discordant cases, prioritize Ki-67 over mitotic count regardless of morphology.\n\nD. WHO Grade $2$ (intermediate), and when discordance exists, choose the lower category to avoid over-treatment, with optional “average-of-hotspots” adjustments to the Ki-67 index.\n\nBackground information for derivation: The WHO grading system for well-differentiated gastrointestinal and pancreatic neuroendocrine tumors utilizes proliferative activity thresholds based on mitoses per $10$ HPF and Ki-67 index. As a widely accepted framework derived from clinicopathologic correlations of proliferation with outcome, the thresholds are:\n$$\n\\text{Grade }1: \\text{mitoses}  2 \\text{ per }10\\ \\text{HPF} \\quad \\text{and} \\quad \\text{Ki-67}  3\\%,\n$$\n$$\n\\text{Grade }2: \\text{mitoses } 2\\text{–}20 \\text{ per }10\\ \\text{HPF} \\quad \\text{or} \\quad \\text{Ki-67 } 3\\%\\text{–}20\\%,\n$$\n$$\n\\text{Grade }3: \\text{mitoses}  20 \\text{ per }10\\ \\text{HPF} \\quad \\text{or} \\quad \\text{Ki-67}  20\\%.\n$$\nWhen the two measures disagree, grading is assigned to the higher category after confirming technical adequacy and correct counting, and morphology is used to distinguish well-differentiated Grade $3$ neuroendocrine tumor from poorly differentiated neuroendocrine carcinoma.",
            "solution": "### Problem Validation\n\n**Step 1: Extract Givens**\n\nThe problem statement provides the following information:\n*   Patient age: $55$ years.\n*   Diagnosis: Resected pancreatic mass, histologically a well-differentiated neuroendocrine neoplasm.\n*   Morphology: Organoid architecture, absence of small-cell or large-cell carcinoma morphology.\n*   Mitotic count: $14$ mitoses per $10$ high-power fields (HPF).\n*   Ki-67 labeling index: $18\\%$.\n*   Ki-67 methodology: Counted approximately $1000$ tumor nuclei in the \"hot spot\" area.\n\nThe problem also includes \"Background information for derivation\" which establishes the axiomatic framework for solving the problem:\n*   **WHO Grading System for well-differentiated GI and pancreatic neuroendocrine tumors:**\n    *   **Grade 1:** mitoses $ 2$ per $10$ HPF **and** Ki-67 $ 3\\%$.\n    *   **Grade 2:** mitoses $2–20$ per $10$ HPF **or** Ki-67 $3\\%–20\\%$.\n    *   **Grade 3:** mitoses $ 20$ per $10$ HPF **or** Ki-67 $ 20\\%$.\n*   **Discordance Rule:** When mitotic count and Ki-67 index disagree, the grade is assigned to the **higher** category after confirming technical adequacy.\n*   **Morphology Use:** Morphology distinguishes well-differentiated Grade $3$ neuroendocrine tumor from poorly differentiated neuroendocrine carcinoma.\n\n**Step 2: Validate Using Extracted Givens**\n\nThe problem is evaluated against the validation criteria:\n*   **Scientifically Grounded:** The problem uses standard, accepted terminology and concepts from the field of surgical pathology and oncology, specifically regarding the classification of neuroendocrine neoplasms. The provided grading criteria and discordance rule are a correct representation of the 2019 World Health Organization (WHO) classification system. The clinical and pathological data are realistic.\n*   **Well-Posed:** The problem provides all necessary data (mitotic count, Ki-67 index) and a complete set of rules (grading thresholds, discordance resolution) to arrive at a single, unique conclusion. The definitions for the grades are mutually exclusive and collectively exhaustive for the given parameters.\n*   **Objective:** The language is clinical, precise, and devoid of subjective or ambiguous terms.\n*   **Completeness and Consistency:** The problem is self-contained. The provided data and the rules for their interpretation are sufficient and do not contradict each other.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. It is scientifically sound, well-posed, objective, and contains sufficient information to derive a unique solution based on the principles provided. The solution process may proceed.\n\n### Solution Derivation\n\nThe solution requires applying the provided WHO grading criteria to the patient's pathological findings.\n\n1.  **Analyze the Mitotic Count:**\n    The patient's tumor has a mitotic count of $14$ mitoses per $10$ HPF. We compare this value to the grading thresholds:\n    *   It is not less than $2$, so it is not Grade $1$.\n    *   It falls within the range for Grade $2$, which is $2–20$ mitoses per $10$ HPF.\n    *   It is not greater than $20$, so it is not Grade $3$.\n    Therefore, based on the mitotic count, the tumor corresponds to **Grade $2$**.\n\n2.  **Analyze the Ki-67 Labeling Index:**\n    The patient's tumor has a Ki-67 index of $18\\%$. We compare this value to the grading thresholds:\n    *   It is not less than $3\\%$, so it is not Grade $1$.\n    *   It falls within the range for Grade $2$, which is a Ki-67 index of $3\\%–20\\%$.\n    *   It is not greater than $20\\%$, so it is not Grade $3$.\n    Therefore, based on the Ki-67 index, the tumor also corresponds to **Grade $2$**.\n\n3.  **Final Grade Determination:**\n    Both the mitotic count ($14$ per $10$ HPF) and the Ki-67 index ($18\\%$) independently place the tumor in Grade $2$. There is no discordance between the two proliferative markers. The definitive WHO grade for this neoplasm is **Grade $2$**.\n\n4.  **Evaluate the Rule for Discordance:**\n    The problem asks for the statement that not only correctly identifies the grade but also describes the best-practice resolution for discordant cases. The \"Background information for derivation\" explicitly states: \"When the two measures disagree, grading is assigned to the **higher category** after confirming technical adequacy and correct counting...\". This is the principle against which the options must be compared.\n\n### Option-by-Option Analysis\n\n**A. WHO Grade $2$ (intermediate), and when mitotic count and Ki-67 index are discordant, assign grade according to the higher category after verifying standardized hot spot counting, adequate sampling, and exclusion of non-tumor nuclei from Ki-67 counts.**\n*   **Grade Identification:** This option correctly identifies the tumor as **WHO Grade $2$**.\n*   **Discordance Rule:** The rule stated, \"assign grade according to the higher category,\" is precisely the rule given in the problem's background information. The additional clause about verifying the counts (\"standardized hot spot counting, adequate sampling, and exclusion of non-tumor nuclei\") is a correct and necessary description of what \"confirming technical adequacy\" entails in pathology.\n*   **Verdict:** **Correct**. This statement is accurate in its entirety.\n\n**B. WHO Grade $3$ (high), because a mitotic count exceeding $10$ per $10$ HPF defines Grade $3$; and discordance should be resolved by averaging the Ki-67 percentage and mitotic count.**\n*   **Grade Identification:** This option incorrectly identifies the tumor as Grade $3$. The correct grade is $2$.\n*   **Reasoning:** The reasoning that a mitotic count exceeding $10$ defines Grade $3$ is factually wrong according to the provided criteria. The threshold for Grade $3$ is $20$ mitoses per $10$ HPF.\n*   **Discordance Rule:** The proposal to resolve discordance by \"averaging\" a count and a percentage is nonsensical from a dimensional analysis perspective and contradicts the established rule of taking the higher grade.\n*   **Verdict:** **Incorrect**.\n\n**C. WHO Grade $1$ (low), because Ki-67 less than $20\\%$ defines Grade $1$; and in discordant cases, prioritize Ki-67 over mitotic count regardless of morphology.**\n*   **Grade Identification:** This option incorrectly identifies the tumor as Grade $1$. The correct grade is $2$.\n*   **Reasoning:** The reasoning that a Ki-67 index less than $20\\%$ defines Grade $1$ is factually wrong. The threshold for Grade $1$ is a Ki-67 index $3\\%$. The patient's value is $18\\%$.\n*   **Discordance Rule:** The proposal to universally \"prioritize Ki-67 over mitotic count\" is incorrect. The established rule is to assign the higher of the two grades.\n*   **Verdict:** **Incorrect**.\n\n**D. WHO Grade $2$ (intermediate), and when discordance exists, choose the lower category to avoid over-treatment, with optional “average-of-hotspots” adjustments to the Ki-67 index.**\n*   **Grade Identification:** This option correctly identifies the tumor as WHO Grade $2$.\n*   **Discordance Rule:** The rule stated, \"choose the lower category,\" is the exact opposite of the correct procedure provided in the background information and established by the WHO. Prognostic data indicates that the higher grade is more predictive of biological behavior.\n*   **Ki-67 Methodology:** The suggestion of \"average-of-hotspots\" contradicts the standard practice, stated in the problem itself, of counting in the \"highest-proliferation ('hot spot') area\" to determine the maximal proliferative potential.\n*   **Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "This final practice problem brings together grading, differentiation, and molecular pathology to tackle a critical diagnostic and therapeutic crossroads. In high-grade ($G3$) neuroendocrine neoplasms, the Ki-67 index alone is not enough; molecular alterations in genes like $TP53$ and $RB1$ are key to distinguishing between a well-differentiated $G3$ NET and a highly aggressive, poorly differentiated neuroendocrine carcinoma (NEC). This distinction has profound implications for patient management, as it dictates the choice between entirely different first-line chemotherapy regimens .",
            "id": "4836180",
            "problem": "A patient with a biopsy-proven gastro-pancreatic neuroendocrine neoplasm presents with widespread hepatic metastases. The tumor is positive for diffuse neuroendocrine markers. The proliferation index on the hotspot is $Ki-67 = 55\\%$. Immunohistochemistry (IHC) demonstrates diffuse strong nuclear p53 overexpression and complete loss of retinoblastoma protein (RB1) staining. Based on core classification principles for gastroenteropancreatic neuroendocrine neoplasms and the relationship between differentiation, proliferation, and canonical tumor suppressor alterations, which classification and first-line systemic therapy is most appropriate to align with this tumor’s biological behavior?\n\nA. Well-differentiated Grade $3$ neuroendocrine tumor; capecitabine plus temozolomide as first-line cytotoxic therapy\n\nB. Poorly differentiated neuroendocrine carcinoma (small-cell or large-cell type); platinum (cisplatin or carboplatin) plus etoposide as first-line chemotherapy\n\nC. Well-differentiated neuroendocrine tumor; long-acting octreotide as first-line antiproliferative therapy\n\nD. Mixed neuroendocrine–non-neuroendocrine neoplasm; oxaliplatin plus fluoropyrimidine (FOLFOX) as first-line therapy directed at the non-neuroendocrine component\n\nE. Poorly differentiated neuroendocrine carcinoma; peptide receptor radionuclide therapy with lutetium-$177$–DOTATATE as first-line therapy",
            "solution": "The validity of the problem statement will be assessed first.\n\n### Step 1: Extract Givens\n- **Patient Condition**: A patient with a biopsy-proven gastro-pancreatic neuroendocrine neoplasm (GEP-NEN).\n- **Disease Extent**: Widespread hepatic metastases.\n- **Tumor Markers**: Positive for diffuse neuroendocrine markers.\n- **Proliferation Index**: $Ki-67 = 55\\%$.\n- **Immunohistochemistry (IHC)**: Diffuse strong nuclear p53 overexpression and complete loss of retinoblastoma protein (RB1) staining.\n- **Question**: To determine the most appropriate classification and first-line systemic therapy.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientific Grounding**: The problem is grounded in the established principles of oncologic pathology and medical oncology, specifically concerning the World Health Organization (WHO) classification and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). The provided data (Ki-67 index, p53 status, RB1 status) are standard parameters used in modern practice to classify these tumors and guide therapy.\n2.  **Well-Posed**: The problem presents a coherent clinical and pathological scenario and asks for a diagnosis and treatment plan. The data provided are sufficient and consistent to arrive at a specific, standard-of-care conclusion based on current clinical guidelines. A unique and meaningful solution exists.\n3.  **Objective**: The problem is articulated using objective, standard medical terminology. The data points (e.g., $Ki-67 = 55\\%$) are quantitative and the IHC findings are described in a standard pathological manner. The question asks for the \"most appropriate\" choice, which in a medical context refers to the evidence-based standard of care, an objective benchmark.\n\n### Step 3: Verdict and Action\nThe problem is scientifically sound, well-posed, and objective. The provided information is internally consistent and reflects a clinically realistic scenario. Therefore, the problem is **valid**. A solution will be derived.\n\n### Derivation of Solution\nThe classification and management of GEP-NENs depend critically on two factors: tumor differentiation (histological appearance) and grade (proliferative activity).\n\n1.  **Tumor Grading**: The grade is determined by the mitotic count or the Ki-67 proliferation index. The WHO classification for GEP-NENs is as follows:\n    - Grade 1 (G1): $Ki-67  3\\%$\n    - Grade 2 (G2): $3\\% \\le Ki-67 \\le 20\\%$\n    - Grade 3 (G3): $Ki-67 > 20\\%$\n    The patient's tumor has a Ki-67 index of $55\\%$, which firmly places it in the Grade $3$ (G3) category.\n\n2.  **Tumor Differentiation and Classification**: Grade $3$ neoplasms are further divided into two clinically and biologically distinct entities:\n    - **Well-differentiated neuroendocrine tumor, Grade 3 (NET G3)**: These tumors have a Ki-67 index $ 20\\%$ but morphologically resemble lower-grade, well-differentiated NETs (organoid, trabecular, or nested growth patterns). Genetically, they are often characterized by mutations in genes like *ATRX* or *DAXX* and typically have wild-type *TP53* and intact *RB1* expression.\n    - **Poorly differentiated neuroendocrine carcinoma, Grade 3 (NEC G3)**: These tumors are high-grade carcinomas by definition, exhibiting features like diffuse sheeting, extensive necrosis, and high mitotic activity. They can have small-cell or large-cell morphology. Critically, their molecular pathogenesis is distinct from NETs and is characterized by inactivating mutations of the tumor suppressor genes *TP53* and *RB1*. On IHC, this translates to abnormal p53 expression (either complete loss or strong, diffuse overexpression, the latter indicating a missense mutation and protein stabilization) and complete loss of RB1 protein staining.\n\n    The patient's tumor exhibits a Ki-67 of $55\\%$, diffuse strong p53 overexpression, and complete loss of RB1. This constellation of findings is the classic signature of a **poorly differentiated neuroendocrine carcinoma (NEC G3)**.\n\n3.  **First-Line Systemic Therapy**: Treatment strategies diverge significantly between NET G3 and NEC G3.\n    - **NET G3**: Treatment is debated but often involves therapies used for G2 NETs, such as cytotoxic chemotherapy (e.g., capecitabine/temozolomide, especially for pancreatic NETs) or, in some cases, peptide receptor radionuclide therapy (PRRT) if somatostatin receptor (SSTR) expression is high.\n    - **NEC G3**: These tumors are highly aggressive and chemosensitive. Their biological behavior is very similar to small cell-lung cancer (SCLC). The undisputed standard of care for first-line treatment of metastatic NEC G3 is platinum-based doublet chemotherapy, most commonly **cisplatin plus etoposide** or **carboplatin plus etoposide**.\n\n    Given the diagnosis of poorly differentiated neuroendocrine carcinoma, the most appropriate first-line therapy is a platinum/etoposide regimen.\n\n### Evaluation of Options\n\n**A. Well-differentiated Grade $3$ neuroendocrine tumor; capecitabine plus temozolomide as first-line cytotoxic therapy**\n- Classification: The classification as a \"well-differentiated\" tumor is incorrect. The p53 and RB1 alterations are hallmarks of a poorly differentiated carcinoma.\n- Therapy: Capecitabine plus temozolomide is primarily used for well-differentiated pancreatic NETs, not the standard first-line for poorly differentiated NECs.\n- Verdict: **Incorrect**.\n\n**B. Poorly differentiated neuroendocrine carcinoma (small-cell or large-cell type); platinum (cisplatin or carboplatin) plus etoposide as first-line chemotherapy**\n- Classification: The classification as a \"poorly differentiated neuroendocrine carcinoma\" is correct, based on the high Ki-67 index combined with the pathognomonic p53 and RB1 alterations.\n- Therapy: Platinum (cisplatin or carboplatin) plus etoposide is the standard, evidence-based first-line chemotherapy for this aggressive disease.\n- Verdict: **Correct**.\n\n**C. Well-differentiated neuroendocrine tumor; long-acting octreotide as first-line antiproliferative therapy**\n- Classification: The classification as a \"well-differentiated\" tumor is incorrect.\n- Therapy: A somatostatin analog like octreotide is used for low-grade, well-differentiated NETs. It is wholly inappropriate as a first-line agent for a highly proliferative ($Ki-67 = 55\\%$) NEC.\n- Verdict: **Incorrect**.\n\n**D. Mixed neuroendocrine–non-neuroendocrine neoplasm; oxaliplatin plus fluoropyrimidine (FOLFOX) as first-line therapy directed at the non-neuroendocrine component**\n- Classification: There is no information in the problem statement to support a diagnosis of a mixed neoplasm (MiNEN). The finding of \"diffuse neuroendocrine markers\" argues against a significant non-neuroendocrine component.\n- Therapy: This therapeutic choice is based on an incorrect and unsubstantiated diagnosis.\n- Verdict: **Incorrect**.\n\n**E. Poorly differentiated neuroendocrine carcinoma; peptide receptor radionuclide therapy with lutetium-$177$–DOTATATE as first-line therapy**\n- Classification: The classification as a \"poorly differentiated neuroendocrine carcinoma\" is correct.\n- Therapy: Peptide receptor radionuclide therapy (PRRT) with Lu-$177$-DOTATATE is indicated for well-differentiated NETs that express somatostatin receptors. Poorly differentiated NECs frequently lack sufficient somatostatin receptor expression for PRRT to be effective and, more importantly, PRRT is not the standard first-line therapy. Aggressive chemotherapy is required.\n- Verdict: **Incorrect**.",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}